A Study of the Safety and Efficacy of Synvisc in Patients With Symptomatic Ankle Osteoarthritis

Genzyme, a Sanofi Company

Overview

This clinical study is to evaluate the safety and efficacy of Synvisc in patients with symptomatic ankle osteoarthritis (OA). Patients will be given Synvisc, with the possible administration of a second injection where insufficient symptomatic pain relief was experienced during the initial 3 months follow up period.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Conditions

Osteoarthritis

Interventions

Synvisc (hylan G-F 20)DEVICE

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with symptomatic OA pain of ankle (talo-crural) Exclusion Criteria: * Patients with current or prior conditions or treatments that would impede measurements of efficacy or safety

Locations (5)

Sportmedizinisches Institut Frankfurt am Main e.V. Orthopadie

Frankfurt, Germany

Johanna Etienne Krankenhaus

Neuss, Germany

Instituti Ortopedici Rizzoli

Bologna, Italy

Ospedale Santa Chiara, Clinica Ortopedica, Universita di Pisa

Pisa, Italy

Outcomes

Primary Outcomes

Pain relief

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.